A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index

BACKGROUND: Cancer cachexia is a syndrome characterized by anorexia and decreased body weight. This study evaluated the efficacy and safety of anamorelin, an orally active, selective ghrelin receptor agonist, in patients with cancer cachexia and a low body mass index (BMI). METHODS: This multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Naito, Tateaki, Uchino, Junji, Kojima, Toru, Matano, Yutaka, Minato, Koichi, Tanaka, Kentaro, Mizukami, Takuro, Atagi, Shinji, Higashiguchi, Takashi, Muro, Kei, Takayama, Koichi, Furuse, Junji, Morishima, Eiichiro, Takiguchi, Toru, Tamura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303784/
https://www.ncbi.nlm.nih.gov/pubmed/35195274
http://dx.doi.org/10.1002/cncr.34154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303784/
https://www.ncbi.nlm.nih.gov/pubmed/35195274
http://dx.doi.org/10.1002/cncr.34154

Ejemplares similares